Leonard P. Guarente, a Founder of the Sirtuin Field, Signs Exclusive Consulting Agreement with Sirtris Pharmaceuticals
06 February 2008 - 12:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that Leonard P. Guarente, PhD, Novartis Professor of Biology at the
Massachusetts Institute of Technology, has signed a new, exclusive
consulting agreement with Sirtris Pharmaceuticals. Dr. Guarente
first joined Sirtris� Scientific Advisory Board as Co-Chair in
November 2007. �We are delighted to have deepened our relationship
with Professor Guarente through this new agreement,� says Christoph
Westphal, MD, PhD, Chief Executive Officer and Vice Chair of
Sirtris Pharmaceuticals. �Professor Guarente, a recognized founder
of the sirtuin field and Co-Chair of our Scientific Advisory Board,
provides critical guidance to our Scientific Advisory Board and his
ideas and research shape our therapeutic efforts.� �I am proud to
serve as Co-Chair of Sirtris� Scientific Advisory Board, and to be
working with Sirtris alone in all sirtuin related fields,� says
Leonard P. Guarente, PhD, the Novartis Professor of Biology at the
Massachusetts Institute of Technology. �Sirtris has built a
Scientific Advisory Board with every key opinion leader in the
sirtuin field, and is well-positioned to develop therapeutics that
target this family of genes for the treatment of diseases of
aging.� �Lenny has made and is making defining contributions to the
sirtuin field,� says David Sinclair, PhD, Co-Founder of Sirtris and
Associate Professor of Pathology at Harvard Medical School.
�Through our ongoing collaborations, we and our Scientific Advisory
Board members hope to further define the therapeutic avenues in
this field,� added Sinclair, who also Co-Chairs Sirtris� Scientific
Advisory Board. Sirtris recently announced positive Phase 1b
clinical trial results with drug candidate SRT501, a proprietary
formulation of resveratrol, in patients with Type 2 Diabetes.
SRT501, which targets the SIRT1 enzyme, was found to be safe and
well-tolerated, and significantly lowered glucose at the two-hour
time point in an oral glucose tolerance test conducted as part of
the 28 day Phase 1b trial of patients with Type 2 Diabetes who were
na�ve to treatment.�Sirtris� new chemical entities (NCEs) activate
SIRT1 and are chemically distinct from and 1000 times more potent,
in vitro, than resveratrol.�The NCEs have been shown to lower
glucose and improve insulin sensitivity in predictive preclinical
models of Type 2 Diabetes. SIRT1 activators have the potential to
be frontline therapy for Type 2 Diabetes. About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that the Company believes
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, the potential therapeutic effects of SIRT1
activators such as SRT501 and NCEs for diseases of aging such as
Type 2 Diabetes:, the progress and results of pre-clinical and
clinical studies of SIRT1 activators, and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of
Sirtris Pharmaceuticals involve significant risks, uncertainties
and assumptions, including risks related to the lack of results
that would provide a basis for predicting whether any of the
Company's product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results,
the Company's potential inability to initiate and complete
pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024